S&P 500   4,522.00 (-1.20%)
DOW   34,416.33 (-0.65%)
QQQ   383.18 (-1.73%)
AAPL   163.04 (-0.44%)
MSFT   323.05 (-1.95%)
FB   306.00 (-1.41%)
GOOGL   2,820.75 (-1.35%)
AMZN   3,390.00 (-1.38%)
TSLA   1,045.45 (-3.61%)
NVDA   306.58 (-4.57%)
BABA   112.35 (-7.91%)
NIO   33.50 (-7.46%)
CGC   9.92 (-4.25%)
AMD   142.34 (-5.53%)
GE   92.52 (-2.85%)
MU   82.32 (-0.68%)
T   23.20 (+0.65%)
F   19.50 (-1.86%)
DIS   145.27 (-1.31%)
PFE   53.49 (+0.85%)
AMC   27.79 (-8.22%)
ACB   5.88 (-4.23%)
BA   196.95 (-2.68%)
S&P 500   4,522.00 (-1.20%)
DOW   34,416.33 (-0.65%)
QQQ   383.18 (-1.73%)
AAPL   163.04 (-0.44%)
MSFT   323.05 (-1.95%)
FB   306.00 (-1.41%)
GOOGL   2,820.75 (-1.35%)
AMZN   3,390.00 (-1.38%)
TSLA   1,045.45 (-3.61%)
NVDA   306.58 (-4.57%)
BABA   112.35 (-7.91%)
NIO   33.50 (-7.46%)
CGC   9.92 (-4.25%)
AMD   142.34 (-5.53%)
GE   92.52 (-2.85%)
MU   82.32 (-0.68%)
T   23.20 (+0.65%)
F   19.50 (-1.86%)
DIS   145.27 (-1.31%)
PFE   53.49 (+0.85%)
AMC   27.79 (-8.22%)
ACB   5.88 (-4.23%)
BA   196.95 (-2.68%)
S&P 500   4,522.00 (-1.20%)
DOW   34,416.33 (-0.65%)
QQQ   383.18 (-1.73%)
AAPL   163.04 (-0.44%)
MSFT   323.05 (-1.95%)
FB   306.00 (-1.41%)
GOOGL   2,820.75 (-1.35%)
AMZN   3,390.00 (-1.38%)
TSLA   1,045.45 (-3.61%)
NVDA   306.58 (-4.57%)
BABA   112.35 (-7.91%)
NIO   33.50 (-7.46%)
CGC   9.92 (-4.25%)
AMD   142.34 (-5.53%)
GE   92.52 (-2.85%)
MU   82.32 (-0.68%)
T   23.20 (+0.65%)
F   19.50 (-1.86%)
DIS   145.27 (-1.31%)
PFE   53.49 (+0.85%)
AMC   27.79 (-8.22%)
ACB   5.88 (-4.23%)
BA   196.95 (-2.68%)
S&P 500   4,522.00 (-1.20%)
DOW   34,416.33 (-0.65%)
QQQ   383.18 (-1.73%)
AAPL   163.04 (-0.44%)
MSFT   323.05 (-1.95%)
FB   306.00 (-1.41%)
GOOGL   2,820.75 (-1.35%)
AMZN   3,390.00 (-1.38%)
TSLA   1,045.45 (-3.61%)
NVDA   306.58 (-4.57%)
BABA   112.35 (-7.91%)
NIO   33.50 (-7.46%)
CGC   9.92 (-4.25%)
AMD   142.34 (-5.53%)
GE   92.52 (-2.85%)
MU   82.32 (-0.68%)
T   23.20 (+0.65%)
F   19.50 (-1.86%)
DIS   145.27 (-1.31%)
PFE   53.49 (+0.85%)
AMC   27.79 (-8.22%)
ACB   5.88 (-4.23%)
BA   196.95 (-2.68%)
NASDAQ:OPNT

Opiant Pharmaceuticals Stock Forecast, Price & News

$29.92
+0.32 (+1.08%)
(As of 12/3/2021 10:31 AM ET)
Add
Compare
Today's Range
$28.91
$31.00
50-Day Range
$22.51
$29.60
52-Week Range
$7.86
$31.89
Volume
1,545 shs
Average Volume
72,289 shs
Market Capitalization
$141.22 million
P/E Ratio
598.52
Dividend Yield
N/A
Beta
0.39
30 days | 90 days | 365 days | Advanced Chart
Receive OPNT News and Ratings via Email

Sign-up to receive the latest news and ratings for Opiant Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Opiant Pharmaceuticals logo

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.

Headlines

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Short Interest Update
December 3, 2021 |  americanbankingnews.com
OPNT: Raises 2021 Full-Year Revenue and Cash Guidance...
November 15, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OPNT
Employees
31
Year Founded
2009

Sales & Book Value

Annual Sales
$29.63 million
Book Value
$8.34 per share

Profitability

Net Income
$-1.86 million
Pretax Margin
-4.32%

Debt

Price-To-Earnings

Miscellaneous

Free Float
3,143,000
Market Cap
$141.22 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/11/2021
Today
12/03/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/03/2022

Social Links


MarketRank

Overall MarketRank

2.22 out of 5 stars

Medical Sector

361st out of 1,391 stocks

Pharmaceutical Preparations Industry

157th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -












Opiant Pharmaceuticals (NASDAQ:OPNT) Frequently Asked Questions

Is Opiant Pharmaceuticals a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opiant Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Opiant Pharmaceuticals stock.
View analyst ratings for Opiant Pharmaceuticals
or view top-rated stocks.

How has Opiant Pharmaceuticals' stock been impacted by Coronavirus?

Opiant Pharmaceuticals' stock was trading at $10.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, OPNT stock has increased by 174.7% and is now trading at $29.80.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Opiant Pharmaceuticals?

Opiant Pharmaceuticals saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 24,400 shares, an increase of 25.8% from the October 31st total of 19,400 shares. Based on an average daily volume of 55,300 shares, the short-interest ratio is presently 0.4 days.
View Opiant Pharmaceuticals' Short Interest
.

When is Opiant Pharmaceuticals' next earnings date?

Opiant Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for Opiant Pharmaceuticals
.

How were Opiant Pharmaceuticals' earnings last quarter?

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) announced its quarterly earnings results on Thursday, November, 11th. The technology company reported $0.56 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.15 by $0.41. Opiant Pharmaceuticals had a trailing twelve-month return on equity of 4.45% and a net margin of 3.58%. During the same quarter in the prior year, the business earned $0.15 EPS.
View Opiant Pharmaceuticals' earnings history
.

What price target have analysts set for OPNT?

1 analysts have issued twelve-month target prices for Opiant Pharmaceuticals' stock. Their forecasts range from $42.00 to $42.00. On average, they anticipate Opiant Pharmaceuticals' share price to reach $42.00 in the next twelve months. This suggests a possible upside of 40.9% from the stock's current price.
View analysts' price targets for Opiant Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Opiant Pharmaceuticals' key executives?

Opiant Pharmaceuticals' management team includes the following people:

What other stocks do shareholders of Opiant Pharmaceuticals own?

What is Opiant Pharmaceuticals' stock symbol?

Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT."

Who are Opiant Pharmaceuticals' major shareholders?

Opiant Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (4.67%), Apis Capital Advisors LLC (2.32%), Two Sigma Advisers LP (1.89%), EAM Investors LLC (1.57%), Two Sigma Investments LP (1.16%) and Geode Capital Management LLC (1.14%). Company insiders that own Opiant Pharmaceuticals stock include Ann L Macdougall, Craig A Collard, David D O'toole, Gabrielle Alison Silver, Matthew R Ruth, Michael Sinclair, Phil Skolnick and Thomas T Thomas.
View institutional ownership trends for Opiant Pharmaceuticals
.

Which major investors are buying Opiant Pharmaceuticals stock?

OPNT stock was purchased by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, EAM Investors LLC, Two Sigma Investments LP, Geode Capital Management LLC, Parkman Healthcare Partners LLC, Essex Investment Management Co. LLC, Dimensional Fund Advisors LP, and Apis Capital Advisors LLC. Company insiders that have bought Opiant Pharmaceuticals stock in the last two years include Ann L Macdougall, Craig A Collard, David D O'toole, Matthew R Ruth, and Thomas T Thomas.
View insider buying and selling activity for Opiant Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Opiant Pharmaceuticals?

Shares of OPNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Opiant Pharmaceuticals' stock price today?

One share of OPNT stock can currently be purchased for approximately $29.80.

How much money does Opiant Pharmaceuticals make?

Opiant Pharmaceuticals has a market capitalization of $140.66 million and generates $29.63 million in revenue each year. The technology company earns $-1.86 million in net income (profit) each year or $0.05 on an earnings per share basis.

How many employees does Opiant Pharmaceuticals have?

Opiant Pharmaceuticals employs 31 workers across the globe.

When was Opiant Pharmaceuticals founded?

Opiant Pharmaceuticals was founded in 2009.

What is Opiant Pharmaceuticals' official website?

The official website for Opiant Pharmaceuticals is www.opiant.com.

Where are Opiant Pharmaceuticals' headquarters?

Opiant Pharmaceuticals is headquartered at 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401.

How can I contact Opiant Pharmaceuticals?

Opiant Pharmaceuticals' mailing address is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. The technology company can be reached via phone at (310) 598-5410, via email at [email protected], or via fax at 917-322-2105.


This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.